Welcome to our dedicated page for Statera Biopharma news (Ticker: STAB), a resource for investors and traders seeking the latest updates and insights on Statera Biopharma stock.
Statera Biopharma Inc (STAB) maintains this comprehensive news hub for stakeholders tracking advancements in immune health therapeutics. Our repository consolidates official announcements, clinical development updates, and strategic partnership disclosures related to the company's innovative drug repurposing strategies.
Investors and researchers will find timely updates on STAB's therapeutic pipeline, including progress in leveraging natural analogs for immune modulation. All content undergoes verification to ensure accurate representation of regulatory milestones and scientific developments.
This resource features essential updates across key operational areas: clinical trial phases, intellectual property developments, collaborative research initiatives, and financial reporting. Each announcement is contextualized within the company's mission to restore homeostasis through pleiotropic drug effects.
For consistent access to verified information about STAB's biopharmaceutical innovations, consider bookmarking this page or setting up news alerts through your preferred financial platform. Always cross-reference materials with official SEC filings and peer-reviewed publications for complete due diligence.
Statera Biopharma (Nasdaq: STAB) will participate in the Benzinga Virtual Healthcare Small Cap Conference on September 29-30, 2021. CEO Michael K. Handley will present on September 29, 2021, from 3:40 - 4:00 p.m. ET. The conference registration can be accessed online. Following the presentation, a webcast will be available in the Investor Relations section of Statera's website. Statera, formerly known as Cytocom, focuses on innovative therapies targeting immune restoration and homeostasis, with clinical programs addressing various diseases.
Statera Biopharma, Inc. (Nasdaq: STAB) will participate in the 2021 Cantor Virtual Global Healthcare Conference from September 27-30, 2021. CEO Michael K. Handley will hold a virtual fireside chat on September 30, 2021, from 12:40 to 1:10 p.m. ET. A webcast of this discussion will be available on the company's Investor Relations section post-conference. Statera focuses on immune therapies for autoimmune diseases, cancers, and emerging viruses, leveraging a proprietary platform with TLR agonists, and has ongoing clinical programs for conditions like Crohn's disease and COVID-19.
Statera BioPharma, Inc. (Nasdaq: STAB) announced its management team, led by President and CEO Michael K. Handley, will ring the Nasdaq Closing Bell on September 2, 2021. This event celebrates the company's new name and ticker symbol after completing a reverse merger on July 27, 2021, transitioning from Cytocom. Statera focuses on developing next-generation immune therapies targeting various diseases, enhancing the immune system's balance. The company expresses optimism regarding its future and ongoing clinical programs for autoimmune conditions, cancer, and COVID-19.
FAQ
What is the current stock price of Statera Biopharma (STAB)?
What is the market cap of Statera Biopharma (STAB)?
